At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

Rome Therapeutics Inc. has synthesized cyclopentene-oxymethylene phosphonamidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

Almost half of a person's DNA consists of retrotransposons, remnants of ancient viral infections that have jumped around the human genome. Retrotransposons are typically kept under wraps by ...

SAN FRANCISCO -- Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF; Biktarvy) or ...

Pretreatment drug resistance (PDR) in patients with HIV varies by subtype, affecting antiretroviral therapy implementation and first-line treatment efficacy. In Hangzhou, 8.4% of newly diagnosed HIV ...

RALEIGH, NC, USA, May 2, 2023/EINPresswire.com/ -- Collaborations Pharmaceuticals, Inc. (CPI) with collaborators at the Research Center of Biotechnology RAS, Moscow ...

Martin Taylor, MD, PhD, a physician investigator in the Department of Pathology at Massachusetts General Hospital and an instructor in Pathology at Harvard Medical School, is the lead corresponding ...

A greater percentage of patients treated with tenofovir alafenamide achieved HBV DNA levels below 20 IU/mL at 24 weeks compared with placebo. The Food and Drug Administration (FDA) has expanded the ...

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.